about
Psychometric properties of a new treatment expectation scale in rheumatoid arthritis: an application of item response theoryA systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes.Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients.Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies.A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK.Investigating Black-White differences in prostate cancer prognosis: A systematic review and meta-analysis.The risk of prostate cancer amongst South Asian men in southern England: the PROCESS cohort study.Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis.Expectations of new treatment in rheumatoid arthritis: developing a patient-generated questionnaireThe relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome.Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS).Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.Disclosure of HIV status: the role of ethnicity among people living with HIV in London.Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36.Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?A randomised trial evaluating anakinra in early active rheumatoid arthritis.Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial.HIV-Related Discrimination Reported by People Living with HIV in London, UKA Comparison of Different Approaches for Costing Medication Use in an Economic EvaluationPain thresholds in rheumatoid arthritis: the effect of tender point counts and disease durationThe impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritisCardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected dataA systematic review of guidelines for managing rheumatoid arthritisCost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter TrialKidney disease in Africans with HIV and tuberculosis
P50
Q30663698-E268C2F6-50F9-402F-9EDE-D546901B6A51Q31105054-E0D82D12-DD50-4FF6-A7E3-D15FC468FD54Q34375843-584F6731-60B4-4460-A346-1AF02D55AFF4Q35174817-9C44D9F5-3762-4B83-AC1B-D67DBF6ADED9Q35767694-95227321-AB3F-4DC5-8CAA-D1E3C38F6FAEQ35906327-023AC316-8F13-4395-A643-3754ABA59FDCQ36095259-B65C85DB-790D-40A4-8809-039C74D07219Q37152796-CAE04661-6CD0-4C4C-9C1C-8F895FF4207EQ37186781-9B44B30F-0D4C-4D64-8616-547A4937E0C3Q37236947-0C852CA2-FC70-4BAC-BB33-5FD8596DC0EBQ37333340-C6A9E7FB-7E4A-4737-87E5-3D4DE242B918Q38809430-929B3462-3F98-47B6-924E-BE762C718F47Q41229720-26EB9725-098E-4296-96D3-F9BDDFEA7E73Q43001305-6B162F88-2E50-4A2D-876F-4768D7E01278Q43623369-6CA07646-DDA0-475C-8927-F8D4B8EC674EQ46049160-3B51F814-6E9F-4C12-8309-6A6F84259D6CQ47102960-2A626992-2751-4F96-860C-1CC2CC890036Q47835758-3854CE0B-3AB2-4041-93F0-832611F43263Q51739307-81F2A61D-DA4B-4880-9754-70322577A783Q55223606-44A27158-F4CE-4CA8-A065-74DB21A7BFE8Q57180189-6ED08F63-4997-48D6-B1DE-1CC60D3E752DQ60441633-A55200CE-5B56-4CD3-8742-8B2C72541EB5Q82534233-D125225E-D0C1-4B3E-908B-A41DDD168785Q82717733-66AB3DE5-CF5D-4357-BBC2-BCB6C1F04F09Q86796730-5930EEF2-C02B-49CD-A926-5903F4158862Q90981842-3B79B82B-D95B-474D-A512-49B902AA84EBQ90984227-02095F85-B19E-4903-B6D0-CC3B3A56372FQ92744894-AE21229B-9F3C-4FFE-A3B4-A031BCDC8325
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
F Ibrahim
@ast
F Ibrahim
@en
F Ibrahim
@es
F Ibrahim
@nl
type
label
F Ibrahim
@ast
F Ibrahim
@en
F Ibrahim
@es
F Ibrahim
@nl
prefLabel
F Ibrahim
@ast
F Ibrahim
@en
F Ibrahim
@es
F Ibrahim
@nl
P1153
12241199600
P31
P496
0000-0002-7069-8024